NCI Corner

Articles from the US National Cancer Institute about issues relevant to the field of thoracic oncology.

Lung Cancer and Smoking Cessation: Opportunities for Progress

By Stephanie R. Land, PhD Tobacco cessation assistance, imperative for tobacco users who seek medical care,1 takes on even greater urgency for individuals who are...

The Budget Landscape with Dr. Douglas R. Lowy

By Erik MacLaren, PhD Posted: August 2018 The National Cancer Institute (NCI) and researchers who rely on the funding it provides have spent much of the...

Small Cell Lung Cancer: The Next Challenge

By Peter Ujhazy, MD, PhD The newfound optimism in the management of lung cancer that infused the research, clinical, and patient communities 12 years ago...

Tools for Smoking Cessation

By Erik J. MacLaren, PhD Posted: October 2017 Scott Gottlieb, MD, Commissioner of the U.S. Food and Drug Administration, said in a recent speech, “There’s probably...

NCI Selects Five Teams of Researchers to Expand Discovery of Predictive Biomarkers for Immunotherapy

Posted: August 2018 In October 2017, the United States National Cancer Institute (NCI) launched a major effort to expand the discovery and validation of predictive...

NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors

Posted: December 2018 Investigators at the National Cancer Institute (NCI) compared the transcriptional profiles of lung cancers from African American patients to those from white...

NCI Corner – Interview with Shakun Malik, MD

Posted: February 2017 By Erik J. Maclaren, PhD 2017 Mesothelioma Clinical Trials Planning Meeting Malignant mesothelioma is one of the most difficult cancers to control using existing...

NCI Corner – Interview with Dinah S. Singer, PHD

By Erik J. MacLaren, PhD Blue Ribbon Panel of the US National Cancer Advisory Board During his State of the Union address in January 2016, President...

NCI Formulary Holds Promise to Speed Clinical Trials

Posted: April 2017 By Erik T. MacLaren, PhD On January 11, the National Cancer Institute (NCI) launched a virtual agent formulary (NCI Formulary): a new public-private...

Meeting News